In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimmer Biomet Holdings Inc.

www.zimmer.com

Latest From Zimmer Biomet Holdings Inc.

AAOS 2019: OSSO VR Develops VR Training Tool For Smith & Nephew's NAVIO Robot, And More On Orthorobotics

Osso VR partnered with Smith & Nephew to develop a VR training tool that will be showcased at this year's American Association of Orthopedic Surgeons' (AAOS) conference, taking place in Las Vegas from March 12-16. Orthopedic robotic systems continue to draw high interest from surgeons. The recent US FDA clearance of Zimmer Biomet's ROSA total knee replacement system will add competition to the current market dominated by Stryker's MAKO and Smith & Nephew's NAVIO.

Commercial Deals

Zimmer Biomet Wins US FDA Nod For Robotically Assisted Knee Replacement System

Zimmer Biomet announced 510 (k) clearance for its Rosa Knee system for robotically assisted total knee replacement surgery.

Approvals Orthopedics

New Anti-Corruption Focus In Mexico May Include Medtech Scrutiny

Recently inaugurated Mexican President Andrés Manuel López Obrador campaigned on a promise to tackle the country’s corruption issues. Medtech Insight spoke to attorney Nicholas Berg, of Ropes & Gray, about what this may mean for device manufacturers doing business in Mexico.

Mexico Compliance

Into 2019: Meaningful Innovation In Medtech Is Reaching A 10-Year Peak

Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.

Financing M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register